AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
In the ALXN1210-TMA-313 Phase III trial, Ultomiris did not achieve statistical significance for event-free survival.
28 July 2026
28 July 2026
In the ALXN1210-TMA-313 Phase III trial, Ultomiris did not achieve statistical significance for event-free survival.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.